ERBB2 and atrial fibrillation: Moreover, the cardiotoxic effects of contemporary oncologic therapies—including anthracyclines, HER2-targeted agents, immune checkpoint inhibitors, and thoracic radiotherapy—can directly impair myocardial structure and function, thereby predisposing to electrical instability and AF [75,76,77,78].